Is ISRG a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Intuitive Surgical (ISRG) rests on Razor-and-blade recurring revenue: Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. The bear case rests on iSRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. Analysts covering it publish targets from $324.00 to $685.00 against a $355.35 price, so even the professionals disagree by 74% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Its business model is razor-and-blade: Intuitive sells or places the large capital systems, then earns high-margin recurring revenue from the single-use instruments and accessories consumed in each procedure, plus service contracts. As the installed base of systems grows and procedure volumes rise, recurring revenue compounds. The company has expanded its platform with newer systems (including the da Vinci 5 and the Ion platform for lung biopsy), and benefits from surgeon training, hospital workflow integration, and a large library of validated procedures that create high switching costs. Intuitive went public in 2000 and is headquartered in Sunnyvale, California. It is the clear leader in surgical robotics with a wide moat, strong margins, and consistent procedure-volume growth, though it trades at a premium valuation that reflects those qualities.
The bull case: what would have to be true for $685.00
The most optimistic published target on ISRG is $685.00, +92.8% from the $355.35 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Razor-and-blade recurring revenue.
Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. As the installed base and procedure volumes grow, this recurring stream compounds with high margins and far more predictability than one-time capital sales.
2. Installed base and switching costs.
Hospitals invest heavily in da Vinci systems, surgeon training, and workflow integration, which creates strong switching costs and a durable relationship. A growing global installed base of systems expands the addressable procedure pool each year and gives Intuitive a platform to introduce new procedures and instruments.
3. Platform expansion and new procedures.
Newer systems like da Vinci 5 and the Ion robotic bronchoscopy platform for lung biopsy extend Intuitive's reach into additional specialties. Each newly validated procedure type and geographic expansion broadens the runway for procedure growth, supported by clinical evidence and surgeon adoption.
The bear case: what would have to be true for $324.00
The most pessimistic published target is $324.00, -8.8% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Intuitive Surgical is worth if the risks below bite instead of the drivers above.
ISRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. Competition is intensifying as Medtronic, Johnson & Johnson, and others develop rival surgical-robotics platforms that could erode Intuitive's dominance over time. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends and currency, and the high valuation leaves little room for execution missteps.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ISRG already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ISRG
29 analysts cover ISRG, with an average target of $484.60 (+36.4% against $355.35) and a split of 24 buy, 8 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ISRG forecast and price target page.
How is ISRG valued? (as of early 2026)
Snapshot for ISRG as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$8 to 9 billion (verify)
- Recurring revenue share: ~80%+ from instruments, accessories, and service
- Operating margin: ~30% (strong)
- Gross margin: ~65% to 68%
- P/E (TTM): ~60x to 75x (premium; verify)
- Dividend: Initiated a modest dividend recently (verify status and yield)
- Procedure growth: High-single to low-double-digit annual growth
- Balance sheet: Strong; large net cash position
Intuitive trades at a high earnings multiple that reflects its dominant market position, high-margin recurring revenue, strong balance sheet, and consistent procedure-volume growth. The premium is the central debate: bulls justify it with the durability of the razor-and-blade model and a long runway, while bears point to multiple-compression risk if procedure growth slows or competitors gain share. Figures are approximate and should be verified against the latest filing.
How do you decide if ISRG is a buy?
Rather than asking whether ISRG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ISRG indirectly through an index or sector ETF before adding more.
What would change your mind on ISRG
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Razor-and-blade recurring revenue stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: iSRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ISRG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ISRG against your real portfolio and see your actual exposure before deciding.
Investing in Intuitive Surgical with AI
Connect the broker you already use and ask Walnut's AI how ISRG fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is ISRG a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Razor-and-blade recurring revenue, with revenue (ttm) at ~$8 to 9 billion (verify). The bear case rests on iSRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. Analysts covering it are spread from $324.00 to $685.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ISRG?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. ISRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $324.00, -8.8% from the $355.35 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for ISRG?
+
Razor-and-blade recurring revenue. Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. The most optimistic analyst target on ISRG is $685.00, +92.8% from the $355.35 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ISRG?
+
ISRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. Competition is intensifying as Medtronic, Johnson & Johnson, and others develop rival surgical-robotics platforms that could erode Intuitive's dominance over time. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends and currency, and the high valuation leaves little room for execution missteps. The most pessimistic published target is $324.00, -8.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Intuitive Surgical do?
+
Dominant surgical-robotics maker (da Vinci), with a razor-and-blade model where instrument and service revenue compounds with procedure volume.
What would have to change for ISRG to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Razor-and-blade recurring revenue) stalling in the reported numbers rather than in the narrative, the risk above (iSRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What is Intuitive Surgical's ticker symbol?
+
ISRG, listed on Nasdaq. The company is Intuitive Surgical, Inc., headquartered in Sunnyvale, California. It went public in 2000 and trades during US market hours at every major US brokerage.
What does Intuitive Surgical do?
+
Intuitive Surgical makes robotic-assisted surgery systems, most notably the da Vinci platform used for minimally invasive procedures in urology, gynecology, general surgery, and other specialties. It also makes the Ion platform for robotic lung biopsy. It earns most revenue from single-use instruments, accessories, and service, not just system sales.
Why is ISRG considered a high-quality stock?
+
Intuitive has a razor-and-blade model where recurring, high-margin revenue from instruments and service grows with procedure volume on a large installed base. High switching costs, strong margins, a clean balance sheet, and consistent procedure growth give it a wide moat that investors value highly.
Walnut is informational, not investment advice, and gives no verdict on ISRG. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature ISRG
ISRG is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.